Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02687815
Recruitment Status : Recruiting
First Posted : February 22, 2016
Last Update Posted : August 1, 2018
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Juan Celedon, MD, University of Pittsburgh

February 11, 2016
February 22, 2016
August 1, 2018
February 22, 2016
July 2020   (Final data collection date for primary outcome measure)
Severe asthma exacerbations [ Time Frame: 48 weeks ]

A severe asthma exacerbation is defined as an exacerbation that meets either of these criteria: 1) Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days OR

2) A hospitalization or ER visit because of asthma, requiring systemic corticosteroids.

Same as current
Complete list of historical versions of study NCT02687815 on Archive Site
  • Severe asthma exacerbations resulting from viral infections [ Time Frame: 48 weeks ]
    A severe viral asthma exacerbation is defined as a severe asthma exacerbation (defined above) along with a positive respiratory viral panel from a nasal blow collected within 72 hours of the exacerbation.
  • Reduction in ICS dose at visit 6 [ Time Frame: 24 weeks ]

    In the absence of moderate or severe asthma exacerbations, participants may have their dose of ICS reduced by 50% if the following criteria are met at visit 6 (halfway through the Trial Phase):

    • ACT score greater than 19
    • Both pre-bronchodilator FEV1 and FEV1/FVC ≥80% of predicted
    • Use of ≤4 puffs of a rescue inhaler per week
    • ≤1 day per month with asthma symptoms preventing full participation in usual daily activities
    • Clinician's judgment regarding adequate asthma control
  • Average cumulative prescribed dose of ICS at the end of the trial [ Time Frame: 48 weeks ]
Same as current
Not Provided
Not Provided
Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)
Vitamin D to Prevent Severe Asthma Exacerbations
This study will determine whether vitamin D3 prevents severe asthma attacks in children who have a serum vitamin D (25(OH)D) level <30 ng/ml and who are being treated with inhaled corticosteroids for asthma. Half the participants will receive vitamin D3 at a dose of 4,000 IU/day, and the other half will receive placebo.

Results from experimental studies, observational studies, two small trials, and a recent meta-analysis suggest that vitamin D reduces the risk of severe asthma exacerbations, and that this protective effect may be due to immune modulation of viral illnesses and/or increased response to inhaled corticosteroids (ICS).

On the basis of those findings, the investigators hypothesize that vitamin D reduces the incidence of severe asthma exacerbations in high-risk school-aged children who have a serum vitamin D level <30 ng/ml and who are being treated with ICS for persistent asthma. The investigators further hypothesize that this protective effect results from reduced incidence of common viral illnesses or enhanced response to ICS. These hypotheses will be tested in a 48-week randomized double-masked placebo-controlled trial of vitamin D3 supplementation to prevent severe asthma exacerbations in 400 children aged 6 to 16 years who have vitamin D insufficiency or deficiency (a serum 25(OH)D <30 ng/ml) and experienced a severe exacerbation in the prior year (a marker of high risk for subsequent events), and who (after a run-in period) are well controlled on medium-dose inhaled corticosteroids.

Our primary aim will determine whether vitamin D3 (4,000 IU/day) reduces the risk of severe asthma exacerbations (our primary outcome) in participating children. Secondary aims will determine the efficacy of vitamin D3 supplementation in: 1) preventing severe asthma exacerbations due to viral infections, 2) reducing the daily and average cumulative dose of inhaled corticosteroids.

Study participation involves 8-9 visits, with each visit lasting between 30-90 minutes. Participation requires completion of study questionnaires, spirometry (breathing tests), and collection of blood samples (to measure vitamin D levels) and urine samples (to measure urinary calcium/creatinine ratios) at some study visits. Since the start of the study, vitamin D levels and urinary calcium/creatinine ratios have been simultaneously measured, to monitor for both vitamin D toxicity and high risk of severe vitamin D deficiency or rickets, which (should they occur) would be managed by a pediatric endocrinologist or a pediatric nephrologist, as appropriate.

All safety data for the study is regularly reviewed by a Data Safety Monitoring Board appointed by the National Heart, Lung and Blood Institute, as well as by the Institutional Review Board of each participating institution. Total study participation will last about one year.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Drug: vitamin D3 4000 IU
    The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
    Other Name: Cholecalciferol
  • Drug: Placebo
    The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
  • Experimental: vitamin D3
    Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
    Intervention: Drug: vitamin D3 4000 IU
  • Placebo Comparator: placebo
    placebo formulations will be in gel cap form and identical to the active drug
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
November 2020
July 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 6 to 16 years old
  • Physician-diagnosed asthma for at least one year
  • At least one severe asthma exacerbation in the previous year
  • Use of asthma medications (daily controller medication [ICS or leukotriene inhibitor] or inhaled β2-agonist [at least three days per week]) for at least six months in the previous year
  • Vitamin D insufficiency (i.e., serum vitamin D (25(OH)D level <30 ng/ml (75 nmol/L))
  • FEV1 ≥70 % of predicted
  • Positive bronchodilator response (i.e., increase in FEV1 ≥8% from baseline after inhaled short acting beta agonist or increased airway responsiveness to methacholine (PC20 ≤8 mg/ml if not on ICS or PC20 ≤16 mg/ml if on ICS)
  • Study protocol (i.e., age-appropriate dose of Fluticasone and no other asthma controller medications) approved by the child's regular doctor
  • Parental consent and child's assent to participate in the study.

Additional inclusion criteria applied after the run-in period, to be eligible for randomization:

  • Adherence with ICS and study medication (≥75% use [at least 21 of 28 days]) during the run-in period
  • Willingness to be randomized and complete study

Exclusion Criteria:

  • Serum calcium >10.8 mg/dl
  • Serum 25(OH) D <14 ng/ml (35 nmol/L)
  • Chronic respiratory disorder other than asthma
  • Severe asthma (intubation for asthma at any time OR ≥3 hospitalizations for asthma in previous year OR ≥6 severe asthma exacerbations in previous year)
  • Hepatic/renal disease, rickets, malabsorption, or other diseases that would affect vitamin D metabolism
  • Current smoking, or former smoking if ≥5 pack-years
  • Immune deficiency, cleft palate or Down's syndrome
  • Treatment with anticonvulsants or ≥1,000 IU/day of vitamin D2 or D3
  • Chronic oral corticosteroid therapy
  • Inability to perform acceptable spirometry
  • Use of investigational therapies or participation in trials 30 days before or during the study
  • Participant is currently breast feeding an infant
  • Pregnancy
  • Weight less than 10 kg
  • Plans to move out of the study site area in the next year

Additional exclusion criteria applied after the run-in period:

  • Any severe asthma exacerbation during the run-in period
  • Need for asthma medications other than ICS and p.r.n. rescue inhalers during the run-in period
Sexes Eligible for Study: All
6 Years to 16 Years   (Child)
Contact: Elizabeth Hartigan, RN 412-692-7060
Contact: Cynthia Granny 412-692-7041
United States
U01HL119952 ( U.S. NIH Grant/Contract )
Not Provided
Plan to Share IPD: No
Juan Celedon, MD, University of Pittsburgh
Juan Celedon, MD
  • Pharmavite
  • National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Juan C. Celedón, MD, DrPH University of Pittsburgh
Principal Investigator: Stephen Wisniewski, PhD University of Pittsburgh
University of Pittsburgh
July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP